Bob has over 23 years of healthcare experience. Most recently, Bob was the Chief Operating Officer of Adams Respiratory Therapeutics. He joined Adams in 2004 as Vice President, Marketing and Business Development and was named Chief Operating Officer in 2006. Bob was a driving force behind the growth of the Adams business, which grew from $60 million to near $500 million under his leadership. He led the diversification of the Adams' portfolio of products by launching Mucinex D and DM, Mucinex for Children, Mucinex Nasal Spray, and acquiring the Delsym brand. Adams was sold to Reckitt Benckiser in 2008 for $2.3 billion.

Bob began his career in 1983 at a Wall Street law firm and joined the legal division of Warner Lambert in 1986. In 1993, he was appointed Warner-Lambert's Vice President of Marketing for the company's upper respiratory and gastrointestinal (GI) consumer products and oversaw several brands, including Benadryl, Sudafed, Zantac 75 and Rolaids. Bob also served as a global vice president for Warner-Lambert's GI and skin care businesses. Following Warner-Lambert's acquisition by Pfizer Inc., Bob served as Vice President, Strategic Planning and Business Development for Pfizer's Consumer Healthcare Division.

Bob is also the non-executive Chairman of Topaz Pharmaceuticals and serves on the Board of Directors of NextWave Pharmaceuticals, both specialty pharmaceutical companies. Bob has an undergraduate and a law degree from Rutgers University.

M’lou has over 19 years experience in the marketing and management of healthcare products. Previously, she was Senior Vice President, Marketing and Advertising for Adams Respiratory Therapeutics, the makers of Mucinex and Delsym.

M’lou joined Adams in 2004 as the Director of Marketing and was a lead architect in the marketing of Mucinex and Delsym, including the development of the award winning Mr. Mucus advertising campaign. She played a key role in growing the Adams business from $60 million to nearly $500 million over the span of 4 years. Adams was sold to Reckitt Benckiser in 2008 for $2.3 billion.

Prior to Adams, M’lou managed a broad spectrum of OTC and HBA businesses at Pfizer Consumer Healthcare and its predecessor Warner Lambert Consumer Healthcare including such brands as Listerine, Lubriderm, Benadryl and e.p.t. Over the course of her career, M’lou has won several marketing, advertising and PR awards. She was named one of the top 50 marketers of the year by Advertising Age in 2006 and one of the top 20 marketers of the year by OTC Perspectives in 2008. She began her career in commercial banking with Chase Manhattan Bank. M’lou received an M.B.A from Columbia University Graduate School of Business and a B.A. from Yale University.

Norm has over 28 years of experience in the pharmaceutical industry. He was most recently the Executive Director of Outsourced Operations for Adams Respiratory Therapeutics where he managed all aspects of the development and supply of third party products until the company was sold to Reckitt Benckiser in 2008.

Norm began his career in R&D and Operations with Johnson & Johnson’s Ortho Pharmaceuticals subsidiary and later worked for R.P. Scherer North America as a Technical Marketing Manager. As General Manager of Materials Processing Technology, a contract manufacturer for the pharmaceutical, chemical and vitamin industries, Norm led a management buy-out of the firm in 1989 and continued as its President & CEO until the company’s sale in 2003.

Norm holds a degree in Pharmacy from the Philadelphia College of Pharmacy & Science and a Masters in Business Administration from Rider University. He is a Registered Pharmacist in New Jersey and Pennsylvania.

May has 8 years of diversified experience in accounting, P&L management, financial and ROI/IRR analysis. Previously, May was Senior Finance Manager for Adams Respiratory Therapeutics, the makers of Mucinex and Delsym.

May joined Adams in 2007 as Finance Manager where she built a marketing finance infrastructure, created cross functional partnerships within the organization, and provided strategic analysis. May also led the forecasting process for all brands and managed trade inventory at Adams.

Prior to Adams, May was the lead finance support for a broad spectrum of OTC and HBA businesses at Pfizer Consumer Healthcare. She began her career at GE Capital in the Financial Management Program and has an undergraduate degree from Isenberg School of Management at the University of Massachusetts.